Trial · NCT05583617
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Stage 1: Percentage of Participants with Adverse Events (AEs) | Baseline up to approximately 5 years | |
| Primary | Stage 2: Objective Response Rate (ORR) | Baseline up to approximately 5 years | |
| Primary | Stage 2: Complete Response (CR) or Stringent Complete Response (sCR) Rate | Baseline up to approximately 5 years | |
| Primary | Stage 2: Rate of Very Good Partial Response (VGPR) or Better | Baseline up to approximately 5 years | |
| Primary | Stage 2: Progression-free Survival (PFS) | Baseline up to approximately 5 years | |
| Primary | Stage 2: Overall Survival (OS) | Baseline up to approximately 5 years | |
| Secondary | Stage 1: Conversion to a Better Response | Baseline up to approximately 5 years | |
| Secondary | Stage 1: PFS | Baseline up to approximately 5 years | |
| Secondary | Stages 1 and 2: Duration of Response (DOR) | Baseline up to approximately 5 years | |
| Secondary | Stage 1: OS | Baseline up to approximately 5 years | |
| Secondary | Stages 1 and 2: Minimal Residual Disease (MRD) Negativity Rate | Baseline up to approximately 5 years | |
| Secondary | Stage 1: ORR | Baseline up to approximately 5 years | |
| Secondary | Stage 1: CR or sCR Rate | Baseline up to approximately 5 years | |
| Secondary | Stage 1: Rate of VGPR or Better | Baseline up to approximately 5 years | |
| Secondary | Stage 2: Stage 1: Percentage of Participants with AEs | Baseline up to approximately 5 years | |
| Secondary | Stages 1 and 2: Time to First Response (for Participants who Achieve a Response of PR or Better) | Baseline up to approximately 5 years | |
| Secondary | Stages 1 and 2: Time to Best Response (for Participants who Achieve a Response of PR or Better) | Baseline up to approximately 5 years | |
| Secondary | Stages 1 and 2: Maximum Concentration Observed (Cmax) | Baseline up to approximately 5 years | |
| Secondary | Stages 1 and 2: Minimum Concentration under Steady-State Conditions within a Dosing Interval (Cmin) | Baseline up to approximately 5 years | |
| Secondary | Stages 1 and 2: Time to Maximum Concentration (Tmax) | Baseline up to approximately 5 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05583617/registered